Immunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
Cancer Biology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Queen's Medical Centre, Nottingham NG2 7UH, UK.
Curr Opin Pharmacol. 2017 Aug;35:66-74. doi: 10.1016/j.coph.2017.05.009. Epub 2017 Jun 14.
Tumours elicit a number of mechanisms to induce a reprogramming of innate and adaptive immune cells to their advantage, inducing a pro-angiogenic phenotype. Investigation of these events is now leading to the identification of specific myeloid and lymphoid cell-targeted therapies, as well as of unexplored off-target activities of clinically relevant chemotherapeutic and metabolic drugs. It is also leading to an enhanced understanding of the interplay between angiogenesis and the immune system, and the value of novel co-targeting approaches using both immunotherapy and anti-angiogenic therapy. Here, we review recently identified mechanisms and potential pharmacological approaches targeting the crosstalk between cancer cells and the host immune system, providing an overview on novel therapeutic opportunities linking immuno-oncology and anti-angiogenic therapy.
肿瘤诱导多种机制，使先天和适应性免疫细胞向有利于肿瘤的方向重编程，诱导血管生成表型。对这些事件的研究目前正在导致特定的髓系和淋巴样细胞靶向治疗的确定，以及对临床相关化疗和代谢药物的未探索的脱靶活性的确定。它还导致对血管生成和免疫系统之间相互作用的增强理解，以及使用免疫疗法和抗血管生成疗法的新型共同靶向方法的价值。在这里，我们综述了最近发现的机制和针对癌细胞与宿主免疫系统相互作用的潜在药理学方法，概述了将肿瘤免疫和抗血管生成治疗联系起来的新的治疗机会。
